FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula 
(I), their racemic mixture, enantiomers, diastereomers and pharmaceutically acceptable salts, possessing properties of Syk inhibitor, pharmaceutical composition and medication based thereof, thereof application, methods of inhibiting and method of treatment with thereof application. In general formula (I) R1 represents hydrogen or C1-C6alkyl, R2 represents phenyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or 5-10-membered heteroaryl, containing 1-2 heteroatoms, selected from N and O, which is optionally substituted with one or several groups, selected from halogen, -NR5R6, -OR7, -S(O)nR8, -C(O)R9, -CN, -C(O)NR5R6, -NR5C(O)R9, -NR5S(O)nR8, -S(O)nNR5R6, C1-C6alkyl, optionally substituted with one, two or three groups, selected from halogen, -OH, -OC1-C4alkyl, -NH2, -NH(C1-C4alkyl), -N(C1-C4alkyl)(C1-C4alkyl), -C(O)N(C1-C4alkyl)(C1-C4alkyl), or 5-8-membered heterocycle, containing 1-2 heteroatoms, selected from N, O, and S, optionally substituted with -SO2(C1-C4alkyl), C3-C6cycloalkyl, 5-8-membered heterocycle, containing 1-2 heteroatoms, selected from N, O and S, optionally substituted with one, two, or three groups, selected from halogen, -OH, C1-C4alkyl, -C1-C4alkyl-OH, ketogroup(oxo), -C(O)C1-C4alkyl, -C(O)C3-C6cycloalkyl, -C(O)C3-C6cycloalkyl-CN, -C(O)C3-C6cycloalkylhalogen, -C(O)NH2, -C(O)NH(C1-C4alkyl), -C(O)N(C1-C4alkyl)(C1-C4alkyl), -C(O)(C1-C4alkyl)-OH, -C(O)(C1-C4alkyl)-O(C1-C4alkyl), -C(O)C1-C4halogenalkyl, -C(O)(C1-C4alkyl)-CN, -C(O)(C1-C4alkyl)-C(O)NH2, -C(O)(C1-C4alkyl)C3-C6cycloalkyl, -C(O)(C1-C4alkyl)-oxetane, C(O)-furanyl, -C(O)-tetrahydrofuranyl, -C(O)(C1-C4alkyl)-SO2(C1-C4alkyl), -O(C1-C4alkyl)-OH, -SO2(C1-C4alkyl), -SO2NH(C1-C4alkyl), -SO2(C1-C4alkyl)(C1-C4alkyl), -SO2C3-C6cycloalkyl, -N(C1-C4alkyl)C(O)(C1-C4alkyl), and 5-6-membered heteroaryl, containing 1-2 nitrogen atoms, optionally substituted with C1-C4alkyl, R3 and R4 are independently selected from hydrogen, C1-C6alkyl, C3-C6cycloalkyl, phenyl, 1,3-dihydroisobenzofuranyl, and 5-6-membered heterocycle, containing 1 nitrogen atom, each of which, except hydrogen, is optionally substituted with one or several groups, selected from halogen, -NR5R6, -OR7, -C(O)OR7, -CN, -C(O)NR5R6, -S(O)nNR5R6, C1-C6alkyl, C3-C6cycloalkyl, 5-6-membered heteroaryl, containing 1-2 nitrogen atoms, and 4-7-membered heterocycle, containing 1-2 heteroatoms, selected from N, O, and S, optionally substituted with one, two or three groups, selected from halogen, hydroxyl, ketogroup(oxo) C1-C4alkyl, -C1-C4alkyl-OH, -C1-C4halogenalkyl, -C(O)NH2, -C(O)NH(C1-C4alkyl), -C(O)N(C1-C4alkyl)(C1-C4alkyl), -C(O)C1-C4alkyl, -C(O)(C1-C4alkyl)-C3-C6cycloalkyl, -C(O)C3-C6cycloalkyl, -C(O)C1-C4halogenalkyl, -C(O)(C1-C4alkyl)-CN, -C(O)(C1-C4alkyl)-OH, -C(O)(C1-C4alkyl)-O-(C1-C4alkyl), -C(O)(C1-C4alkyl)N(C1-C4alkyl)2, -C(O)(C1-C4alkyl)-SO2-(C1-C4alkyl), -C(O)(C1-C4alkyl)-C3-C6cycloalkyl, -SO2(C1-C4alkyl), -SO2(C1-C4halogenalkyl), -SO2C3-C6cycloalkyl, -SO2NH2 and pyrimidinyl, or R3 and R4 together with N atom, which they bind to, can form 5-10-membered monocyclic, fused bicyclic or spirocyclic ring, optionally containing 1 additional nitrogen atom, which is optionally substituted with one or several groups, selected from -NR5R6, -C(O)OR7, -C(O)NR5R6, -NR5S(O)nR8, -NR5C(O)NR10R11, and C1-C6alkyl optionally substituted with hydroxyl, amino, -NHSO2(C1-C4alkyl), -NH(C1-C4alkyl), -N(C1-C4alkyl)(C1-C4alkyl), or -NHC(O)NH2, m equals 0 or 1, n equals 2.
EFFECT: obtaining novel compounds.
28 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
| NEW TRIAZOLOPYRASINE DERIVATIVES AND THEIR APPLICATION | 2013 |
|
RU2643361C2 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS AN MTOR/PI3K INHIBITOR | 2015 |
|
RU2658912C1 |
| 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, METHOD FOR ITS OBTAINING AND ITS APPLICATION | 2019 |
|
RU2804127C2 |
| THIENO[2,3-c]QUINOLIN-4-ONE DERIVATIVES, USEFUL IN TREATMENT OF ERK-DEPENDENT DISEASE | 2011 |
|
RU2574398C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2687093C1 |
| PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
